Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings Inc (XERS) is a biopharmaceutical innovator developing ready-to-use therapies for complex conditions in endocrinology, neurology, and gastroenterology. This page aggregates official company announcements, regulatory milestones, and research developments for stakeholders tracking its progress.
Access timely updates on XERS' FDA-approved products including Gvoke (severe hypoglycemia), Recorlev (Cushing's Syndrome), and proprietary formulation platforms like XeriSol and XeriJect. Our curated news feed covers clinical trial results, partnership announcements, manufacturing updates, and financial disclosures essential for understanding the company's trajectory in advanced biotherapeutics.
This resource serves investors and healthcare professionals needing verified information about XERS' patient-centric solutions. Content is organized chronologically with clear sourcing to facilitate efficient research. Bookmark this page for structured access to earnings reports, regulatory filings, and scientific advancements from one of biopharma's most innovative formulation specialists.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) announces the release of its fourth quarter and full year 2021 financial results on March 10, 2022, prior to U.S. market open. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. The company specializes in developing therapies for endocrinology, neurology, and gastroenterology, with products like Gvoke® and Keveyis®. Xeris also has ongoing development programs supported by proprietary formulation technologies.
Xeris Biopharma (Nasdaq: XERS) announced that its CEO, Paul R. Edick, will participate in the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 12:00pm Eastern Time. The event will include a fireside chat format and will be accessible via a live webcast on the company's investor relations website. Xeris is focused on developing unique therapies in endocrinology, neurology, and gastroenterology, with products like Gvoke® for severe hypoglycemia and Recorlev® for Cushing’s syndrome, among others.
Xeris Biopharma Holdings (NASDAQ: XERS) announced that its drug Recorlev (levoketoconazole) is now exclusively available through PANTHERx Rare Specialty Pharmacy. This FDA-approved treatment for Cushing's syndrome enhances patient access through the Xeris CareConnection program, offering $0 co-pay for insured individuals and comprehensive support services. Recorlev aims to address the needs of patients unable to undergo surgery. It received positive Phase 3 study results, demonstrating significant efficacy in reducing cortisol levels.
Xeris Biopharma Holdings (NASDAQ: XERS) reported preliminary full-year 2021 pro forma net sales between
PANTHERx Rare has been chosen by Xeris Pharmaceuticals as the exclusive U.S. distribution partner for Recorlev (levoketoconazole), a newly FDA-approved treatment for endogenous hypercortisolemia in adults with Cushing's syndrome. This medication is crucial for patients for whom surgery is not viable. Cushing's syndrome is prevalent in adults aged 30-50, particularly affecting women. Recorlev will be available commercially in Q1 2022. Important safety warnings include hepatotoxicity and QT prolongation risks.
Xeris Biopharma Holdings (NASDAQ: XERS) announced that CEO Paul R. Edick will present at the H.C. Wainwright BioConnect 2022 conference from January 10-13, 2022. The presentation will highlight the FDA approval of Recorlev® and other recent company developments. It will be available on-demand starting January 10, 2022, at 7:00 a.m. E.T. Xeris specializes in therapies for endocrinology, neurology, and gastroenterology, with existing products like Gvoke® and Keveyis®. The company is headquartered in Chicago, IL.
Xeris Biopharma Holdings (NASDAQ: XERS) announced a private placement agreement with Armistice Capital, expected to close on January 3, 2022, for gross proceeds of approximately $30.0 million. The deal involves issuing 10,238,908 shares of common stock at $2.93 each and warrants to purchase an additional 5,119,454 shares at $3.223. Proceeds will be allocated to operational support, product marketing, clinical trials, and general corporate purposes. The shares will not be registered under the Securities Act upon issuance and will require a resale registration statement.
Xeris Biopharma announced FDA approval for Recorlev (levoketoconazole), a treatment for Cushing's syndrome in adults where surgery isn't an option. The decision follows the acquisition of Strongbridge Biopharma on October 5, 2021. Safety and efficacy were supported by positive results from two pivotal Phase 3 studies (SONICS and LOGICS) involving 166 patients. A commercial launch is planned for Q1 2022, positioning Xeris to meet the treatment needs of this patient population.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) announced the UK launch of Ogluo® (glucagon injection) through its commercialization partner, Tetris Pharma, for treating severe hypoglycemia in diabetes patients aged 2 and over. This follows a licensing deal in July for Ogluo's commercialization in the UK and EU. Xeris estimates around 5 million people in the UK are at risk of severe hypoglycemia, with only 10-20% currently prescribed glucagon. The launch aims to increase accessibility and provide a ready-to-use solution for emergencies.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) reported strong third-quarter performance with pro forma net sales of $22.5 million, driven by Gvoke and Keveyis, expected to reach $76-$80 million for 2021. The acquisition of Strongbridge Biopharma was finalized on October 5, 2021, with integration completed and $50 million in synergies anticipated. The company boasts a robust cash position of approximately $100 million at year-end, along with a 12-month extension on its debt facility, pushing principal repayments to 2023.
